Fibrocell Science (FCSC) Sees Large Volume Increase

Fibrocell Science Inc (NASDAQ:FCSC) shares saw an uptick in trading volume on Friday . 2,312,869 shares traded hands during trading, an increase of 88% from the previous session’s volume of 1,231,108 shares.The stock last traded at $0.75 and had previously closed at $0.69.

Several research firms have weighed in on FCSC. Zacks Investment Research upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. HC Wainwright upped their target price on Fibrocell Science from $5.70 to $7.60 and gave the stock a “buy” rating in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.21.

In other Fibrocell Science news, major shareholder Randal J. Kirk bought 2,727,273 shares of the business’s stock in a transaction on Monday, December 11th. The stock was purchased at an average cost of $0.77 per share, for a total transaction of $2,100,000.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.10% of the stock is owned by corporate insiders.

An institutional investor recently bought a new position in Fibrocell Science stock. Pura Vida Investments LLC purchased a new stake in Fibrocell Science Inc (NASDAQ:FCSC) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 297,000 shares of the company’s stock, valued at approximately $909,000. Pura Vida Investments LLC owned about 2.02% of Fibrocell Science as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 31.64% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

What are top analysts saying about Fibrocell Science? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit